[Objective] To establish the model for anti-hepatitis B virus (HBV) drug evaluation in duck fetal hepatocytes.[Method] The ordinary PCR assay was employed to confirm the embryonated,un-hatched,duck eggs layed by the duck hepatitis B virus (DHBV)-infected ducks.Duck fetal hepatocytes were isolated and primary cultured.The SYBR green dye-based fluorescence quantitative PCR assay was established for detection of DHBV-DNA in primary duck fetal hepatocytes.[Result] Duck fetal hepatocytes were isolated from 18-22-day-old duck embryo and their optimized parameters of isolation and culture were determined.The SYBR green dye-based quantitative PCR assay for detection of DHBVDNA was established in primary duck fetal hepatocytes.[Conclusion] The study established a model to evaluate anti-HBV drug by the SYBR green dye-based fluorescence quantitative PCR assay for detection of DHBV-DNA in primary duck fetal hepatocytes.Furthermore,the model was demonstrated to be a sample,specific,sensitive and repeatable assay for screening and evaluation of anti-HBV drugs.%[目的]建立基于鸭胚原代肝细胞的抗乙肝药物筛选及评价模型.[方法]采用PCR技术鉴定鸭乙肝病毒(DHBV)感染鸭胚,分离感染鸭胚肝细胞原代培养,运用建立的荧光定量PCR技术检测鸭胚肝细胞DHBV-DNA复制水平,从而建立基于鸭胚原代肝细胞的抗乙肝药物评价模型.[结果]选择18 ～22日龄鸭胚建立了优化的鸭胚肝细胞原代培养方法和鸭胚肝细胞中DHBV-DNA水平的荧光定量PCR检测技术.[结论]该研究建立了基于鸭胚肝细胞的抗乙肝药物评价模型,经实践证实该模型具有特异、灵敏、重复性好和操作简便的优点,适用于抗乙肝化合物的筛选与评价.
展开▼
